SCHEMBL1992149

SCHEMBL1992149

COC(=O)C(=O)c1cn(C(=O)OC(C)(C)C)c2ccsc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.36
BCHE P06276 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
HTR6 P50406 1/20 0.34
FEN1 P39748 1/20 0.33
EED O75530 1/20 0.32
RBBP4 Q09028 1/20 0.32
SUZ12 Q15022 1/20 0.32
EZH2 Q15910 1/20 0.32
AEBP2 Q6ZN18 1/20 0.32
ALDH1A1 P00352 2/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
BUB1 O43683 1/20 0.31
GBA1 P04062 1/20 0.31
NR1H2 P55055 1/20 0.30
PIM1 P11309 1/20 0.30
MARK3 P27448 1/20 0.30
MAP4K2 Q12851 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1988689 0.86 L3MBTL1 (0.46) L3MBTL1BCHEKMT2AMEN1HTR6
SCHEMBL1994321 0.81 BCHE (0.35) L3MBTL1BCHEKMT2AMEN1HTR6
SCHEMBL1992807 0.78 L3MBTL1 (0.49) L3MBTL1BCHEKMT2AMEN1HTR6
SCHEMBL28935614 0.74 L3MBTL1 (0.46) L3MBTL1BCHEKMT2AMEN1HTR6
SCHEMBL28935624 0.74 PTGDR2 (0.48) L3MBTL1BCHEKMT2AMEN1HTR6
SCHEMBL28935550 0.72 L3MBTL1 (0.41) L3MBTL1BCHEKMT2AMEN1HTR6
SCHEMBL28935653 0.72 L3MBTL1 (0.43) L3MBTL1BCHEHTR6FEN1ALDH1A1
SCHEMBL1996984 0.71 L3MBTL1 (0.65) L3MBTL1BCHEHTR6FEN1TSHR
SCHEMBL28935605 0.69 L3MBTL1 (0.43) L3MBTL1BCHEHTR6FEN1EPHX1
SCHEMBL1992228 0.68 POLB (0.39) L3MBTL1KMT2AMEN1FEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO L3MBTL1 3898/4885BCHE 4442/4885KMT2A 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.